BPC-157 vs Octreotide
Overview
BPC-157 is primarily a healing & recovery peptide, while Octreotide is used for hormonal.
This page compares BPC-157 and Octreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| BPC-157 | Octreotide | |
|---|---|---|
| Category | Healing & Recovery | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 250-500 mcg | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) |
| Frequency | daily | Every 4 weeks (LAR); two to four times daily (immediate-release) |
| Reported benefits | Accelerated wound healing, tendon and ligament repair, gut health improvement, reduced inflammation, neuroprotective effects | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers |
| Reported side effects | Generally well-tolerated. Rare: injection site reactions, mild fatigue | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain |
Key differences
Primary use. BPC-157 is categorised under Healing & Recovery, while Octreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026. Octreotide: FDA-approved.
Dosing. BPC-157 is typically dosed at 250-500 mcg (daily). Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)).
Can you stack them?
Some protocols combine peptides, but stacking BPC-157 and Octreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between BPC-157 and Octreotide?
- BPC-157 is primarily a healing & recovery peptide, while Octreotide is used for hormonal. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Octreotide is FDA-approved for one or more indications.
- What is BPC-157 used for?
- Healing & recovery, gut health.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- Can you take BPC-157 and Octreotide together?
- Some users combine peptides within a single protocol, but stacking BPC-157 and Octreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is BPC-157 or Octreotide FDA-approved?
- BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Octreotide is FDA-approved for one or more indications.
Read the full articles
- BPC-157 — full monograph: mechanism, research, dosing & references
- Octreotide — full monograph: mechanism, research, dosing & references